Vinayak Muralidhar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8091600/publications.pdf

Version: 2024-02-01

100	2,034	361413	265206
papers	citations	20	42
		h-index	g-index

100	100	100	4100
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 2015, 35, S129-S150.	9.6	225
2	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	9.6	220
3	Pyruvate Kinase Isoform Expression Alters Nucleotide Synthesis to Impact Cell Proliferation. Molecular Cell, 2015, 57, 95-107.	9.7	209
4	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1905-1912.	1.6	121
5	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. Journal of Urology, 2015, 194, 343-349.	0.4	109
6	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostateâ€specific antigen screening in 2012. Cancer, 2020, 126, 717-724.	4.1	64
7	Merkel Cell Carcinoma: A Population Analysis on Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1247-1257.	4.9	57
8	Association Between Treatment at a High-Volume Facility and Improved Survival forÂRadiation-Treated Men With High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 683-690.	0.8	57
9	Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?. International Journal of Radiation Oncology Biology Physics, 2016, 96, 313-317.	0.8	51
10	Transfusion in Head and Neck Free Flap Patients. Otolaryngology - Head and Neck Surgery, 2015, 152, 449-457.	1.9	45
11	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	2.5	45
12	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. New England Journal of Medicine, 2019, 380, 2070-2072.	27.0	42
13	Definition and Validation of â€œFavorable High-Risk Prostate Cancerâ€• Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.8	40
14	Use and early mortality outcomes of active surveillance in patients with intermediateâ€risk prostate cancer. Cancer, 2019, 125, 3164-3171.	4.1	35
15	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	4.1	27
16	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer, 2016, 122, 1505-1512.	4.1	27
17	Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Diseases of the Colon and Rectum, 2016, 59, 187-193.	1.3	25
18	Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. JAMA Oncology, 2020, 6, 1630.	7.1	25

#	Article	IF	Citations
19	Financial worry and psychological distress among cancer survivors in the United States, 2013â€”2018. Supportive Care in Cancer, 2021, 29, 5523-5535.	2.2	25
20	Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. Journal of Urology, 2019, 202, 973-978.	0.4	24
21	Association Between Older Age and Increasing Gleason Score. Clinical Genitourinary Cancer, 2015, 13, 525-530.e3.	1.9	23
22	Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. Journal of Contemporary Brachytherapy, 2016, 1, 1-6.	0.9	23
23	Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 2016, 117, E20-8.	2.5	22
24	Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 76-85.	1.6	21
25	Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. Radiation Oncology, 2015, 10, 155.	2.7	20
26	Multilingual Analysis of the Quality and Readability of Online Health Information on the Adverse Effects of Breast Cancer Treatments. JAMA Surgery, 2020, 155, 781.	4.3	20
27	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. Brachytherapy, 2019, 18, 186-191.	0.5	18
28	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9â€“10 Prostate Cancer. European Urology, 2019, 75, 35-41.	1.9	18
29	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. European Urology Oncology, 2022, 5, 100-103.	5.4	18
30	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2021, 109, 1279-1285.	0.8	18
31	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. JCO Oncology Practice, 2022, 18, e204-e218.	2.9	18
32	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	1.6	17
33	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with â‰¥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	1.0	16
34	Conservative management of lowâ€risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer, 2019, 125, 3338-3346.	4.1	15
35	Prostate cancerâ€specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities. Prostate, 2020, 80, 1128-1133.	2.3	15
36	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	2.5	14

#	Article	IF	Citations
37	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 953-959.	1.3	14
38	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 330.e19-330.e25.	1.6	13
39	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.5	13
40	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	1.5	13
41	Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma. JCO Oncology Practice, 2021, 17, e1489-e1501.	2.9	13
42	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. Prostate Cancer and Prostatic Diseases, 2020, 23, 179-183.	3.9	12
43	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. European Urology, 2022, 81, 466-473.	1.9	12
44	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clinical Genitourinary Cancer, 2016, 14, e299-e305.	1.9	11
45	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	4.9	10
46	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 621-627.	0.8	10
47	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.8	9
48	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clinical Genitourinary Cancer, 2020, 19, 246-254.e5.	1.9	9
49	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. Cancer, 2021, 127, 2213-2221.	4.1	9
50	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer, 2020, 126, 1407-1412.	4.1	8
51	Disparities in Mortality from Larynx Cancer: Implications for Reducing Racial Differences. Laryngoscope, 2021, 131, E1147-E1155.	2.0	8
52	Recent relocation and decreased survival following a cancer diagnosis. Preventive Medicine, 2016, 89, 245-250.	3.4	7
53	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	1.9	7
54	Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Advances in Radiation Oncology, 2017, 2, 140-147.	1.2	7

#	Article	IF	Citations
55	Validation of a subclassification for highâ€risk prostate cancer in a prospective cohort. Cancer, 2020, 126, 2132-2138.	4.1	7
56	Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. Radiotherapy and Oncology, 2021, 161, 241-250.	0.6	7
57	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e25-542.e32.	1.6	6
58	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 904-911.	0.8	6
59	Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 157.e15-157.e20.	1.6	6
60	Psychological Distress and Access to Mental Health Services Among Cancer Survivors: a National Health Interview Survey Analysis. Journal of General Internal Medicine, 2021, 36, 3243-3245.	2.6	6
61	Local management of preinvasive and clinical T1-3 penile cancer: utilization of diverse treatment modalities. Future Oncology, 2020, 16, 955-960.	2.4	5
62	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. Brachytherapy, 2015, 14, 511-516.	0.5	4
63	Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. Prostate International, 2017, 5, 89-94.	2.3	3
64	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. International Journal of Radiation Oncology Biology Physics, 2020, 108, 936-940.	0.8	3
65	Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?. Practical Radiation Oncology, 2021, 11, e426-e433.	2.1	3
66	US Primary Care vs Specialty Care Trainee Positions and Physician Incomes: Trends From 2001 to 2019. Journal of Graduate Medical Education, 2021, 13, 385-389.	1.3	3
67	Clinical characterization of radiation-associated muscle-invasive bladder cancer. Urology, 2021, 154, 208-214.	1.0	3
68	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 735.e9-735.e15.	1.6	2
69	Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: AÂsingle-center case series and national database comparison. Journal of the American Academy of Dermatology, 2021, 84, 168-172.	1.2	2
70	Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. Advances in Radiation Oncology, 2021, 6, 100608.	1.2	2
71	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). Cancer Genetics, 2021, 258-259, 61-68.	0.4	2
72	Characteristics of radiation-associated bladder cancer compared to primary bladder cancer. Journal of Clinical Oncology, 2020, 38, 582-582.	1.6	2

#	Article	IF	Citations
73	Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. Brachytherapy, 2019, 18, 198-203.	0.5	1
74	Mental Distress and Mental Health Services Receipt in Foreign-Born Survivors of Cancer: a National Health Interview Survey Analysis. Journal of General Internal Medicine, 2021, 36, 2495-2498.	2.6	1
75	Association between travel distance and use of postoperative radiation therapy among men with organ-confined prostate cancer: Does geography influence treatment decisions?. Journal of Clinical Oncology, 2021, 39, 24-24.	1.6	1
76	Surgical management versus combination radiotherapy in Gleason score 9-10 prostate cancer.. Journal of Clinical Oncology, 2020, 38, 135-135.	1.6	1
77	The association of androgen deprivation therapy and anxiety among 78,000 patients with localized prostate cancer patients.. Journal of Clinical Oncology, 2017, 35, 19-19.	1.6	1
78	Laboratory eligibility criteria as potential barriers to participation by black men in prostate cancer clinical trials.. Journal of Clinical Oncology, 2018, 36, 73-73.	1.6	1
79	Mental distress and mental health services receipt in foreign-born survivors of cancer: A national health interview survey analysis.. Journal of Clinical Oncology, 2020, 38, e19001-e19001.	1.6	1
80	Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer.. Journal of Clinical Oncology, 2020, 38, 101-101.	1.6	1
81	Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8â€“10 prostate cancer. Brachytherapy, 2021, 20, 1-9.	0.5	0
82	Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.. Journal of Clinical Oncology, 2021, 39, 205-205.	1.6	0
83	Factors influencing noncompletion of radiotherapy among men with localized prostate cancer.. Journal of Clinical Oncology, 2021, 39, 199-199.	1.6	0
84	Radiation Delay Is Okay, but Where Is the Evidence?â€”Reply. JAMA Oncology, 2021, 7, 464.	7.1	0
85	Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer.. Journal of Clinical Oncology, 2015, 33, 32-32.	1.6	0
86	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. Journal of Clinical Oncology, 2015, 33, 34-34.	1.6	0
87	Re-irradiation of the pelvis for a genitourinary second malignant neoplasm or a local recurrence after full-dose pelvic radiotherapy for a pelvic cancer: Experience in a high-volume cancer center.. Journal of Clinical Oncology, 2016, 34, 494-494.	1.6	0
88	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 54-54.	1.6	0
89	Socioeconomic disparities in the receipt of radiation for node-positive prostate cancer.. Journal of Clinical Oncology, 2016, 34, 53-53.	1.6	0
90	Brachytherapy boost and cancer-specific mortality in favorable high-risk and other high-risk prostate cancer.. Journal of Clinical Oncology, 2016, 34, 52-52.	1.6	0

#	Article	IF	Citations
91	Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.. Journal of Clinical Oncology, 2016, 34, 33-33.	1.6	0
92	National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 50-50.	1.6	0
93	Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.. Journal of Clinical Oncology, 2017, 35, e545-e545.	1.6	0
94	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. Journal of Clinical Oncology, 2017, 35, 18-18.	1.6	0
95	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. Journal of Clinical Oncology, 2018, 36, 78-78.	1.6	0
96	Active surveillance and watchful waiting for low-risk prostate cancer in black patients: A population-based analysis.. Journal of Clinical Oncology, 2019, 37, 10-10.	1.6	0
97	Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 941-948.	4.9	0
98	Doublecortin expression in prostate adenocarcinoma and neuroendocrine tumors.. Journal of Clinical Oncology, 2020, 38, 161-161.	1.6	0
99	Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.. Journal of Clinical Oncology, 2020, 38, 337-337.	1.6	0
100	Body fat composition as biomarker for clinical outcomes and treatment tolerance in high-risk prostate cancer.. Journal of Clinical Oncology, 2022, 40, 159-159.	1.6	0